ClinicalTrials.gg
RecruitingNCT07378098Updated May 1, 2026

to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia

A Phase 3 interventional study of KLH-2109+ Leurprorelin acetate Placebo and KLH-2109 Placebo + Leurprorelin acetate in Menorrhagia and Uterine Fibroids, sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus.

The primary objectives of this trial were to answer the following questions:

  • Does KLH-2109 lower the amount of menstrual bleeding?
  • Does KLH-2109 reduce menstrual bleeding?
  • Is KLH-2109 safe for participants to use?

Investigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective.

Participants will be required to follow:

  • Take either KLH-2109 or the common treatment as a pill
  • Visit the clinic regularly for health checkups and safety tests
  • Keep track of their bleeding and any health changes during the study
Read the detailed description

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3

02

Conditions studied

  • Menorrhagia
  • Uterine Fibroids

Keywords

  • Uterine Fibroids
  • Menorrhagia
03

In context

Menorrhagia

206 studies on the registry are indexed under Menorrhagia; 35 are open to participants now.

This study's planned enrollment of 254 is above the median of 95 across 149 interventional studies indexed under Menorrhagia.

Browse Menorrhagia studies →

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with uterine fibroids

Exclusion criteria

Exclusion Criteria:

  • Metrorrhagia or anovulatory bleeding
  • Patients with a history of total hysterectomy or bilateral oophorectomy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
254 participants (estimated)

Study arms

  • Experimental
    KLH-2109+ Leurprorelin acetate Placebo

    KLH-2109: 200mg/day for 24 weeks(PO, QD) Leurprorelin acetate Placebo: Once every 4 weeks, subcutaneous injection

    Drug: KLH-2109+ Leurprorelin acetate Placebo

  • Active comparator
    KLH-2109 Placebo + Leurprorelin acetate

    KLH-2109 Placebo: 24 weeks(PO, QD) Leurprorelin acetate : 1.88mg or 3.75mg, Once every 4 weeks, subcutaneous injection

    Drug: KLH-2109 Placebo + Leurprorelin acetate

Interventions

  • DrugKLH-2109+ Leurprorelin acetate Placebo

    KLH-2109 200mg/day for 24 weeks(PO, QD) Leurprorelin acetate Placebo: Once every 4 weeks, subcutaneous injection

    Also known as: KLH-2019+ Leurprorelin acetate Placebo

  • DrugKLH-2109 Placebo + Leurprorelin acetate

    KLH-2109 Placebo: for 24 weeks(PO, QD) Leurprorelin acetate Placebo: 1.88mg or 3.75mg , Once every 4 weeks, subcutaneous injection

    Also known as: KLH-2019 Placebo + Leurprorelin acetate Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a total PBAC score < 10

    Proportion of subjects with a total PBAC score \< 10 from Week 6 to the day before Week 12 after administration of the investigational product

    Time frame: Week 6 to the day before Week 12

Secondary outcomes

  1. Proportion of subjects with a total PBAC score < 10

    Proportion of subjects with a total PBAC score \< 10 from Week 2 to the day before Week 6 after administration of the investigational product

    Time frame: Week 6 , Week12, Week 18, Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 17 phase 3 interventional studies under Menorrhagia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 35. This study's planned 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 30, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Sep 3, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07378098
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Feb 3, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Sep 3, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Deageun Song
Contact
daegeun.song@jwhealthcare.com
82-2-840-6792
Jeong Yeol Park
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion